Information about ADRs explored by pharmacovigilance approaches: A qualitative review of studies on antibiotics, SSRIs and NSAIDs

BMC Clinical Pharmacology

Volumn 9, Issue , 2009, Pages

  Aagaard, Lise ^a,b,c   Hansen, Ebba Holme ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FKL Research Centre for Quality in Medicine Use   (Denmark)

^c DANISH MEDICINES AGENCY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ARTHROTEC; BROMFENAC; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; FLUCONAZOLE; FLUVOXAMINE; GATIFLOXACIN; GLUCOSE; IBUPROFEN; LEVOFLOXACIN; MACROLIDE; MELOXICAM; MINOCYCLINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SODIUM; SPARFLOXACIN; TESTOSTERONE; UNINDEXED DRUG; VENLAFAXINE;

ACHILLES TENDON RUPTURE; ADVERSE DRUG REACTION; ALOPECIA; ANAPHYLAXIS; BLEEDING; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTATIC HEPATITIS; CLASSIFICATION; DESCRIPTIVE RESEARCH; DRUG FATALITY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EYE TOXICITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GLOSSITIS; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY INJURY; LACTATION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MANIA; MEDICAL LITERATURE; MENTAL DISEASE; NAUSEA; OBSERVATIONAL STUDY; PANCREATITIS; PEMPHIGUS; PHOTOTOXICITY; QUALITATIVE RESEARCH; REVIEW; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SIDE EFFECT; SKIN TOXICITY; SODIUM BLOOD LEVEL; SOFT TISSUE INFECTION; STEVENS JOHNSON SYNDROME; STOMATITIS; SUICIDE; TENDINITIS; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TONGUE DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME; CASE CONTROL STUDY; COHORT ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 63049117319     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-9-4     Document Type: Review

References (98)

1. Inman WHW Vessey MP Westerholm B Engelund A Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs BMJ 1970, 25:203-9
2. Dukes MNG The effects of drug regulation Lancaster: MTP Press Limited 1985
3. Horton R Vioxx, the implosion of Merck, and the after shocks at the FDA Lancet 2004, 364:1995-6 10.1016/S0140-6736(04)17523-5 15582041
4. Tscholl D Langer F Wendler O Wilkens H Georg T Schäfers HJ Pulmonary thromboendarterectomy- risk factors for early survival and hemodynamic improvement Eur J Cardiothorac Surg 2001, 19:771-6 10.1016/ S1010-7940(01)00686-8 11404129
5. Stefan H Bernatik J Knorr J Visual field defects due to antiepileptic drugs Nervenartz 1999, 70:552-5 10.1007/s001150050479
6. Watkins P COMT inhibitors and liver toxicity Neurology 2000, 55:S51-2 11147510
7. Aagaard L Soendergaard B Andersen E Kampmann JP Hansen EH Creating knowledge about adverse drug reactions: A critical analysis of the Danish reporting system from 1968 to 2005 Soc Sci Med 2007, 65(6):1296-309 10.1016/j.socscimed.2007.04.026 17566621
8. Hansen EH Technology assessment of pharmaceuticals - the necessity of user perspective Cah Sociol Demogr Med 1990, 30:313-27 2224579
9. Hansen EH Technology assessment in a user perspective - experiences with drug technology Int J Technol Assess Health Care 1992, 8:150-65 1601585
10. Dukes MNG The law and ethics of the pharmaceutical industry Amsterdam, Elsevier 2006
11. Loke YK Derry S Aronson JK A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone Br J Clin Pharmacol 2004, 57(5):616-621 1884501 15089815 10.1111/ j.0306-5251.2003.02055.x
12. Loke YK Price D Herxheimer A Systematic reviews of adverse effects: framework for a structured approach BMC Medical Research Methodology 2007, 7:32 1933432 17615054 10.1186/1471-2288-7-32
13. Strom BL Pharmacoepidemiology West Sussex, John Wiley & Sons Ltd 2005
14. Rawlins MD Thompson JW Pathogenesis of adverse drug reactions Textbook of Adverse. Drug Reactions Davies DM 1977:10-31
15. Czeizel AE Rockenbauer M Sørensen HT Olsen J A population-based case-control teratologic study of oral erythromycin treatment during pregnancy Reprod Toxicol 1999, 13:531-6 10.1016/S0890-6238(99)00046-5 10613401
16. Seeger JD West WA Fife D Noel GJ Johnson LN Walker AM Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population Pharmacoepidemiol Drug Saf 2006, 15:784-92 10.1002/pds.1214 16456878
17. Chyský V Kapila K Hullmann R Arcieri G Schacht P Echols R Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use. Emphasis on joint evaluation Infection 1991, 19:289-96 10.1007/BF01644970 1917049
18. Derby LE Jick H Henry DA Dean AD Cholestatic hepatitis associated with flucloxacillin Med J Aust 1993, 158:596-00 8479374
19. Jick H Derby LE Dean AD Henry DA Flucloxacillin and cholestatic hepatitis Med J Aust 1994, 18:160-525
20. Derby LE Jick H Henry DA Dean AD Erythromycin-associated cholestatic hepatitis Med J Aust 1993, 158:600-2 8479375
21. Heymann AD Chodick G Kramer E Green M Shalev V Pemphigus variant associated with penicillin use: A case-cohort study of 363 patients from Israel Arch Dermatol 2007, 143:704-7 10.1001/archderm.143.6.704 17576935
22. Clark DW Layton D Wilton LV Pearce GL Shakir SA Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: Experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database Drug Saf 2001, 24:1143-54 10.2165/00002018-200124150-00005 11772147
23. Inmann W Pearce G Wilton L Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy Eur J Clin Pharmacol 1994, 46:115-8 10.1007/BF00199872 8039528
24. Sachs B Riegel S Seebeck J Beier R Schichler D Barger A Merk HF Erdmann S Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: Differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use Drug Saf 2006, 29:1087-00 10.2165/00002018-200629110-00008 17061914
25. Fleisch F Hartmann K Kuhn M Fluoroquinolone-induced tendinopathy: Also occurring with levofloxacin Infection 2000, 28:256-7 10.1007/ s150100070050 10961538
26. Leone R Venegoni M Motola D Moretti U Piazzetta V Cocci A Resi D Mozzo F Velo G Burzilleri L Montanaro N Conforti A Adverse drug reactions related to the use of fluoroquinolone antimicrobials: An analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions Drug Saf 2003, 26:109-20 10.2165/ 00002018-200326020-00004 12534327
27. Pierfitte C Royer RJ Moore N Bégaud B The link between sunshine and phototoxicity of sparfloxacin Br J Clin Pharmacol 2000, 49:609-12 2015040 10848726 10.1046/j.1365-2125.2000.00212.x
28. Frothingham R Glucose homeostasis abnormalities associated with use of gatifloxacin Clin Infect Dis 2005, 41:1269-76 10.1086/496929 16206101
29. Hedenmalm K Spigset O Peripheral sensory disturbances related to treatment with fluoroquinolones J Antimicrob Chemother 1996, 37:831-7 10.1093/jac/37.4.831 8722551
30. Abouesh A Stone C Hobbs WR Antimicrobial-induced mania (antibiomania): A review of spontaneous reports J Clin Psychopharmacol 2002, 22:71-81 10.1097/00004714-200202000-00012 11799346
31. Smith K Leyden JJ Safety of doxycycline and minocycline: A systematic review Clin Ther 2005, 27:1329-42 10.1016/j.clinthera.2005.09.005 16291409
32. Hällgren J Tengvall-Linder M Persson M Wahlgren CF Stevens-Johnson syndrome associated with ciprofloxacin: A review of adverse cutaneous events reported in Sweden as associated with this drug J Am Acad Dermatol 2003, 49:S267-9 10.1016/S0190-9622(03)00478-X 14576649
33. Warner A Clarithromycin - a precipitant for acute psychotic stress Psychosomatics 2000, 41:539 10.1176/appi.psy.41.6.539 11110120
34. ADRAC Drug-induced cholestatic hepatitis from common antibiotics MJA 1992, 157:531 1479973
35. Greco S Mazzaglia G Caputi AP Pagliaro L Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics Ann Pharmacother 1997, 31:1548 9416400
36. Björnsson E Lindberg J Olsson R Liver reactions to oral low-dose tetracyclines Scand J Gastroenterol 1997, 32:390-5 10.3109/ 00365529709007690 9140164
37. Hernández-Díaz S Rodríguez LA Steroids and risk of upper gastrointestinal complications Am J Epidemiol 2001, 153:1089-93 10.1093/aje/153.11.1089 11390328
38. Mockenhaupt M Kelly JP Kaufman D Stern RS SCAR Study Group The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: A multinational perspective J Rheumatol 2003, 30:2234-40 14528522
39. Lacroix I Lapeyre-Mestre M Bagheri H Pathak A Montastruc JL Nonsteroidal anti-inflammatory drug-induced liver injury: A case-control study in primary care Fundam Clin Pharmacol 2004, 18:201-6 10.1111/ j.1472-8206.2004.00224.x 15066135
40. Lipworth L Friis S Blot WJ McLaughlin JK Mellemkjaer L Johnsen SP Nørgaard B Olsen JH A population-based cohort study of mortality among users of ibuprofen in Denmark Am J Ther 2004, 11:156-63 10.1097/ 00045391-200405000-00002 15133529
41. Ashworth NL Peloso PM Muhajarine N Stang M A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen J Rheumatol 2004, 31:951-6 15124256
42. Morant SV Pettitt D MacDonald TM Burke TA Goldstein JL Application of a propensity score to adjust for channelling bias with NSAIDs Pharmacoepidemiol Drug Saf 2004, 13:345-53 10.1002/pds.946 15170763
43. Martin RM Biswas P Mann RD The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: Cohort study Br J Clin Pharmacol 2000, 50:35-42 2014964 10886116 10.1046/ j.1365-2125.2000.00229.x
44. Lugardon S Lapeyre-Mestre M Montastruc JL Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): A case/non-case study from the French Pharmacovigilance Database Eur J Clin Pharmacol 2004, 60:673-7 10.1007/s00228-004-0813-5 15517227
45. Durrieu G Olivier P Montastruc JL COX-2 inhibitors and arterial hypertension: An analysis of spontaneous case reports in the Pharmacovigilance database Eur J Clin Pharmacol 2005, 61:611-4 10.1007/ s00228-005-0964-z 16133552
46. Clinard F Sgro C Bardou M Hillon P Dumas M Kreft-Jais C Escousse A Bonithon-Kopp C Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database Eur J Clin Pharmacol 2004, 60:279-83 10.1007/s00228-004-0761-0 15103437
47. Brinker A Goldkind L Bonnel R Beitz J Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin Drugs Aging 2004, 21:479-84 10.2165/ 00002512-200421070-00005 15132714
48. La Grenade L Lee L Weaver J Bonnel R Karwoski C Governale L Brinker A Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors Drug Saf 2005, 28:917-24 10.2165/00002018-200528100-00008 16180941
49. Polimeni G Salvo F Cutroneo P Morreale I Patrizio Caputi A Adverse reactions induced by NSAIDs and antibacterials: Analysis of spontaneous reports from the Sicilian regional database Drug Saf 2006, 29:449-59 10.2165/00002018-200629050-00006 16689558
50. Conforti A Leone R Moretti U Mozzo F Velo G Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: Results of spontaneous reporting from a Northern Italian area Drug Saf 2001, 24:1081-90 10.2165/00002018-200124140-00006 11735663
51. Ahmad SR Kortepeter C Brinker A Chen M Beitz J Renal failure associated with the use of celecoxib and rofecoxib Drug Saf 2002, 25:537-44 10.2165/ 00002018-200225070-00007 12093311
52. van Puijenbroek EP Egberts AC Heerdink ER Leufkens HG Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: An example with diuretics and non-steroidal anti-inflammatory drugs Eur J Clin Pharmacol 2000, 56:733-8 10.1007/s002280000215 11214785
53. Lapeyre-Mestre M de Castro AM Bareille MP Del Pozo JG Requejo AA Arias LM Montastruc JL Carvajal A Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: Analysis from national spontaneous reporting systems Fundam Clin Pharmacol 2006, 20:391-5 10.1111/ j.1472-8206.2006.00416.x 16867024
54. Leone R Conforti A Ghiotto E Moretti U Valvo E Velo GP Nimesulide and renal impairment Eur J Clin Pharmacol 1999, 55:151-4 10.1007/ s002280050610 10335911
55. Brown EG Waller PC Sallie BA Tiaprofenic acid and severe cystitis Postgrad Med J 1998, 74:443-4 2360981 9799928 10.1136/pgmj.74.873.443
56. Verrico MM Weber RJ McKaveney TP Ansani NT Towers AL Adverse Drug Events Involving COX-2 Inhibitors Ann Pharmacother 2003, 37:1203-13 10.1345/ aph.1A212 12921500
57. Kahn LH Styrt BA Necrotizing soft tissue infections reported with nonsteroidal antiinflammatory drugs Ann Pharmacother 1997, 31:1034-9 9296245
58. Layton D Wilton LV Shakir SA Safety profile of celecoxib as used in general practice in England: Results of a prescription-event monitoring study Eur J Clin Pharmacol 2004, 60:489-01 10.1007/s00228-004-0788-2 15278327
59. Layton D Hughes K Harris S Shakir SA Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data Rheumatology (Oxford) 2003, 42:1332-41 10.1093/rheumatology/keg376 12810929
60. Layton D Riley J Wilton LV Shakir SA Safety profile of rofecoxib as used in general practice in England: Results of a prescription-event monitoring study Br J Clin Pharmacol 2003 55 166 74 1894735 12580988 10.1046/j.1365-2125.2003.01763.x
61. Layton D Heeley E Shakir SA Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data J Clin Pharm Ther 2004, 29:171-81 10.1111/j.1365-2710.2004.00550.x 15068407
62. Kasliwal R Layton D Harris S Wilton L Shakir SA A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data Drug Saf 2005, 28:803-16 10.2165/ 00002018-200528090-00005 16119973
63. Layton D Heeley E Hughes K Shakir SA Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and Meloxicam in general practice in England using Prescription-event monitoring (PEM) data Rheumatology 2003, 42:1342-53 10.1093/rheumatology/ keg379 12832706
64. Layton D Heeley E Hughes K SAW Shakir Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data Rheumatology 2003, 42:622-31 10.1093/ rheumatology/keg141 12709537
65. Layton D Marshall V Boshier A Friedmann P Shakir SA Serious Skin Reactions and Selective COX-2 Inhibitors. A Case Series from Prescription-Event Monitoring In England Drug Saf 2006, 29:687-96 10.2165/00002018-200629080-00005 16872242
66. Layton D Hughes K Harris S Shakir SA Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data Rheumatology 2003, 42:1354-64 10.1093/rheumatology/ keg401 12867585
67. Onder G Pellicciotti F Gambassi G Bernabei R NSAID-Related Psychiatric Adverse Events. Who is at risk? Drugs 2004, 64:2619-27 10.2165/ 00003495-200464230-00001 15537366
68. Fraunfelder FW Solomon J Mechelas TJ Ocular Adverse Effects Associated With Cyclooxygenase-2 Inhibitors Arch Ophthalmol 2006, 124:277-79 10.1001/archopht.124.2.277 16476901
69. Ziemer M Wiesend CL Vetter R Weiss J Blaschke S Norgauer J Mockenhaupt M Cutaneous Adverse Reactions to Valdecoxib Distinct From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Arch Dermatol 2007, 143:711-16 10.1001/archderm.143.6.711 17576936
70. Hunter EB Johnston PE Tanner G Pinson CW Awad JA Bromfenac (Duract)- Associated Hepatic Failure Requiring Liver Transplantation AJG 1999, 94:2299-01 10.1111/j.1572-0241.1999.01321.x
71. ADRAC Premature closure of the fetal ductus arteriosus after maternal use of non-steroidal anti-inflammatory drugs MJA 1998, 169:270-71 9762067
72. Schillevoort I van Puijenbroek EP de Boer A Ross RA Jansen PA Leufkens HG Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: A case-control study using spontaneous reports Int Clin Psychopharmacol 2002, 17:75-9 10.1097/00004850-200203000-00006 11892721
73. Movig KLL Leufkens HGM Lenderink AW Eberts ACG Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly Eur J Clin Pharmacol 2002, 58:143-48 10.1007/ s00228-002-0438-5 12012148
74. Bell S Shipman M Bystritsky A Haifley T Fluoxetine Treatment and Testosterone Levels Annals of Clinical Psychiatry 2006, 18:19-22 10.1080/ 10401230500464612 16517449
75. Trenque T Piednoir D Frances C Millart H Germain ML Reports of withdrawal syndrome with the use of SSRIs: A case/non-case study in the French Pharmacovigilance database Pharmacoepidemiol Drug Saf 2002, 11:281-3 10.1002/pds.704 12138595
76. Gony M Lapeyre-Mestre M Montastruc JL Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: A pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs Clin Neuropharmacol 2003, 26:142-5 10.1097/00002826-200305000-00007 12782916
77. Hedenmalm K Sundström A Spigset O Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs) Pharmacoepidemiol Drug Saf 2006, 15:719-25 10.1002/pds.1270 16783834
78. Goldstein DJ Corbin LA Sundell KL Effects of First-Trimester Fluoxetine Exposure on the Newborn Obstet Gynecol 1997, 89:713-8 10.1016/ S0029-7844(97)00070-7 9166307
79. Spigset O Hägg S Bate A Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: Data from the World Health Organization database of adverse drug reactions Int Clin Psychopharmacol 2003, 18:157-61 10.1097/00004850-200305000-00006 12702895
80. Khan A Khan S Kolts R Brown WA Suicide Rates in Clinical Trials of SSRIs, other Antidepressants and placebo: Analysis of FDA Reports Am J Psychiatry 2003, 160:790-92 10.1176/appi.ajp.160.4.790 12668373
81. Egberts ACG Meyboom RHB De Koning FHP Bakker A Leufkens HGM Non-puerperal lactation associated with antidepressant drug use Br J Clin Pharmacol 1997, 44:277-81 2042834 9296322 10.1046/ j.1365-2125.1997.00652.x
82. Kvande KT Madsen S Selective serotonin reuptake inhibitors and pancreatitis Tidsskr Nor Laegeforen 2001, 121:177-8 11475194
83. Stahl MMS Lindquist M Pettersson M Edwards IR Sanderson JH Taylor NFA Fletcher AP Schou JS Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system Eur J Clin Pharmacol 1997, 53:163-69 10.1007/s002280050357 9476026
84. Spigset O Adverse Reactions of Selective Serotonin Reuptake Inhibitors. Reports from a Spontaneous Reporting System Drug Saf 1999, 20:277-87 10.2165/00002018-199920030-00007 +10221856
85. Sanz EJ De-las-Cuevas C Kiuru A Bate A Edwards R Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis Lancet 2005, 365:482-87 15705457
86. Price JS Waller PC Wood SM MacKay AV A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal Br J Clin Pharmacol 1996, 42:757-63 2042719 8971432 10.1046/j.1365-2125.1996.00498.x
87. Layton D Clark DW Pearce GL Shakir SA Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England Eur J Clin Pharmacol 2001, 57:167-76 10.1007/s002280100263 11417450
88. Edwards JG Inman WH Wilton L Pearce G Prescription-event monitoring of 10,401 patients treated with fluvoxamine Br J Psychiatry 1994, 164:387-95 10.1192/bjp.164.3.387 7993416
89. MacKay FJ Dunn NR Wilton LV Pearce GL Freemantle SN Mann RD A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies Pharmacoepidemiol Drug Saf 1997, 6:235-46 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3 15073774
90. De Abajo FJ Montero D Garcia Rodriguez LA Madurga M Antidepressants and Risk of Upper Gastrointestinal Bleeding Pharmacology & Tocicology 2006, 98:304-10
91. Gram LF Blødning og trombocytopeni ved behandling med selektive SSRI [In Danish] Ugeskr Laeger 1999, 161:2697-98 10434797
92. Demers JC Malone M Serotonin Syndrome Induced by Fluvoxamine and Mirtazapine Ann Pharmacother 2001, 35:1217-20 10.1345/aph.10418 11675850
93. Aagaard L Soendergaard B Andersen E Kampmann JP Hansen EH Creating knowledge about adverse drug reactions: A critical analysis of the Danish reporting system from 1968 to 2005 Soc Sci Med 2007, 65:1296-309 10.1016/j.socscimed.2007.04.026 17566621
94. Aagaard L Stenver DI Hansen EH Structures and processes in spontaneous ADR reporting systems: A comparative study of Australia and Denmark Pharm World Sci 2008, 30:563-70 10.1007/s11096-008-9210-y 18350372
95. Mann RD Drug safety alerts - a review of "current problems" Pharmacoepidemiol Drug Saf 1992, 1:269-79 10.1002/pds.2630010509
96. Meyboom RHB Gribnau FWJ Hekster YA de Koning GHP Egberts ACG Characteristics of Topics in Pharmacovigilance in the Netherlands Clin Drug Invest 1996, 12:207-19 10.2165/00044011-199612040-00006
97. Hauben M Zhou X Quantitative methods in pharmacovigilance: Focus on signal detection Drug Saf 2003, 26:159-86 10.2165/ 00002018-200326030-00003 12580646
98. Matsushita Y Kuroda Y Niwa S Sonehara S Hamada C Yoshimura I Criteria Revision and Performance Comparison of Three Methods of Signal Detection Applied to the Spontaneous Reporting Database of a Pharmaceutical Manufacturer Drug Saf 2007, 30:715-26 10.2165/00002018-200730080-00008 17696584